Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

351 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.
Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, Cox AD, Wilson O, Kirschmeier P, Der CJ. Roberts PJ, et al. J Biol Chem. 2008 Sep 12;283(37):25150-63. doi: 10.1074/jbc.M800882200. Epub 2008 Jul 9. J Biol Chem. 2008. PMID: 18614539 Free PMC article.
Posttranslational lipid modification of Rho family small GTPases.
Mitin N, Roberts PJ, Chenette EJ, Der CJ. Mitin N, et al. Methods Mol Biol. 2012;827:87-95. doi: 10.1007/978-1-61779-442-1_6. Methods Mol Biol. 2012. PMID: 22144269
Clinical use of crizotinib for the treatment of non-small cell lung cancer.
Roberts PJ. Roberts PJ. Biologics. 2013;7:91-101. doi: 10.2147/BTT.S29026. Epub 2013 Apr 26. Biologics. 2013. PMID: 23671386 Free PMC article.
KRAS mutation: should we test for it, and does it matter?
Roberts PJ, Stinchcombe TE. Roberts PJ, et al. J Clin Oncol. 2013 Mar 10;31(8):1112-21. doi: 10.1200/JCO.2012.43.0454. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401440 Review.
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.
Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, Habibi S, Zamboni B, Müller M, Brunner M, Sharpless NE, Zamboni WC. Combest AJ, et al. Oncologist. 2012;17(10):1303-16. doi: 10.1634/theoncologist.2012-0274. Epub 2012 Sep 19. Oncologist. 2012. PMID: 22993143 Free PMC article.
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE. Roberts PJ, et al. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1. J Natl Cancer Inst. 2012. PMID: 22302033 Free PMC article.
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Roberts PJ, et al. J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921461 Review.
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK. Deng J, et al. Among authors: roberts pj. Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3. Cancer Discov. 2018. PMID: 29101163 Free PMC article.
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.
He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ, Strum JC, Malik R, Sharpless NE. He S, et al. Among authors: roberts pj. Sci Transl Med. 2017 Apr 26;9(387):eaal3986. doi: 10.1126/scitranslmed.aal3986. Sci Transl Med. 2017. PMID: 28446688 Free PMC article.
351 results
Jump to page